Assuming secondary is required, the following results were found.

  • Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) | Small Molecules | News Channels - PipelineReview.com

    Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) Details Hits: 158 If approved, Mayzent® (siponimod) will be the first and only oral...

    https://mschristian.org/index.php/articles/2-uncategorised/9270-novartis-receives-positive-chmp-opinion-for-mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-spms-small-molecules-news-channels-pipelinereview-com
  • Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) | Small Molecules | News Channels - PipelineReview.com

    Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) DetailsHits: 158If approved, Mayzent® (siponimod) will be the first and only oral treatment...

    https://mschristian.org/index.php/blog/novartis-receives-positive-chmp-opinion-for-mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-spms-small-molecules-news-channels-pipelinereview-com
  • Siponimod Delays Time to Wheelchair in Secondary Progressive MS - Neurology Times

    population has suggested that siponimod (Mayzent, Novartis) may have an additional long-term benefit for patients with secondary progressive multiple sclerosis (MS) beyond the study’s core findings. The oral selective sphingosine-1-phosphate receptor...

    https://mschristian.org/index.php/articles/2-uncategorised/8782-siponimod-delays-time-to-wheelchair-in-secondary-progressive-ms-neurology-times
  • Diagnosis and Symptoms of Secondary Progressive MS

    If you have secondary progressive multiple sclerosis (#SPMS), you most likely started out with the relapsing-remitting type (#RRMS). The shift to SPMS often happens slowly, and it can be hard to know for sure if your condition has changed. One way to...

    https://mschristian.org/index.php/articles/2-uncategorised/9089-diagnosis-and-symptoms-of-secondary-progressive-ms
  • Siponimod Delays Time to Wheelchair in Secondary Progressive MS - Neurology Times

    population has suggested that siponimod (Mayzent, Novartis) may have an additional long-term benefit for patients with secondary progressive multiple sclerosis (MS) beyond the study’s core findings. The oral selective sphingosine-1-phosphate receptor...

    https://mschristian.org/index.php/blog/siponimod-delays-time-to-wheelchair-in-secondary-progressive-ms-neurology-times
  • What to know about secondary progressive multiple sclerosis (SPMS)

    Table of contents Secondary progressive multiple sclerosis is a later stage of multiple sclerosis. Instead of having symptom relapses and remissions, a person's symptoms steadily get worse over time. Most people, but not everyone, with...

    https://mschristian.org/index.php/blog/what-to-know-about-secondary-progressive-multiple-sclerosis-spms-1
  • Fast Five Quiz: Secondary Progressive Multiple Sclerosis - Medscape

    resolve to some degree or resolve completely are the hallmark of RRMS. Most patients with RRMS will eventually develop secondary progressive multiple sclerosis (SPMS); however, with the advent of newer disease-modifying therapies (DMTs) and due to...

    https://mschristian.org/index.php/articles/2-uncategorised/8781-fast-five-quiz-secondary-progressive-multiple-sclerosis-medscape
  • Multiple sclerosis treatments delay progression of the disease

    disability in Multiple Sclerosis. It showed that early treatment -- particularly within five years of onset -- delayed the secondary progressive stage of MS, which is characterised by an ongoing increase of disability. It showed that early treatment --...

    https://mschristian.org/index.php/blog/multiple-sclerosis-treatments-delay-progression-of-the-disease
  • Functional activity of anti-LINGO-1 antibody opicinumab requires target engagement at a secondary binding site

    it contains two LINGO-1 binding sites: a classical site utilizing its complementarity-determining regions and a cryptic secondary site involving Li81 light chain framework residues that recruits a second LINGO-1 molecule only after engagement of the...

    https://mschristian.org/index.php/blog/functional-activity-of-anti-lingo-1-antibody-opicinumab-requires-target-engagement-at-a-secondary-binding-site
  • Diagnosis and Symptoms of Secondary Progressive MS

    If you have secondary progressive multiple sclerosis (#SPMS), you most likely started out with the relapsing-remitting type (#RRMS). The shift to SPMS often happens slowly, and it can be hard to know for sure if your condition has changed. One way to...

    https://mschristian.org/index.php/blog/diagnosis-and-symptoms-of-secondary-progressive-ms
  • Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

    to reduce the annualized relapse rate over Aubagio®* (teriflunomide) in patients with relapsing forms of MS (RMS)[1] Key secondary endpoints of delaying time to confirmed disability progression were also met[1]; additional secondary endpoints will be...

    https://mschristian.org/index.php/blog/novartis-ofatumumab-demonstrates-superiority-versus-aubagio-in-two-head-to-head-phase-iii-multiple-sclerosis-studies-1
  • Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

    to reduce the annualized relapse rate over Aubagio®*(teriflunomide) in patients with relapsing forms of MS (RMS)[1] Key secondary endpoints of delaying time to confirmed disability progression were also met[1]; additional secondary endpoints will be...

    https://mschristian.org/index.php/blog/novartis-ofatumumab-demonstrates-superiority-versus-aubagio-in-two-head-to-head-phase-iii-multiple-sclerosis-studies
  • Fast Five Quiz: Secondary Progressive Multiple Sclerosis - Medscape

    resolve to some degree or resolve completely are the hallmark of RRMS. Most patients with RRMS will eventually develop secondary progressive multiple sclerosis (SPMS); however, with the advent of newer disease-modifying therapies (DMTs) and due to...

    https://mschristian.org/index.php/blog/fast-five-quiz-secondary-progressive-multiple-sclerosis-medscape
  • Secondary Progressive

    (SPMS) Begins with an RMS classification that becomes consistently progressive and includes more frequent relapses with minor remission. Loss of physical and mental function are accumulated without recovery between attacks.

    https://mschristian.org/index.php/articles/79-q-and-a/80-ms-glossary/8023-secondary-progressive
  • Multiple sclerosis treatments delay progression of the disease

    disability in Multiple Sclerosis. It showed that early treatment -- particularly within five years of onset -- delayed the secondary progressive stage of MS, which is characterised by an ongoing increase of disability. It showed that early treatment --...

    https://mschristian.org/index.php/articles/2-uncategorised/5282-multiple-sclerosis-treatments-delay-progression-of-the-disease
  • Mobility Support Devices for Secondary Progressive MS: Braces, Walking Devices, and More

    Overview Secondary progressive multiple sclerosis (SPMS) can cause a variety of symptoms, including dizziness, fatigue, muscle weakness, muscle tightness, and loss of sensation in your limbs. Over time, these symptoms may affect your ability to walk....

    https://mschristian.org/index.php/blog/mobility-support-devices-for-secondary-progressive-ms-braces-walking-devices-and-more
  • MS Risk Nearly Doubles 15 Years Following Teen Concussion - Medscape

    "We also found a significantly increased risk among males and not females" starting at about 8 years post-concussion in a secondary analysis, lead study author Christopher Povolo, BSc, of the Department of Clinical Neurological Sciences, Schulich School...

    https://mschristian.org/index.php/blog/ms-risk-nearly-doubles-15-years-following-teen-concussion-medscape
  • #ECTRIMS2019 - Longer DMT Use and Female Sex Seen to Protect Against SPMS Conversion - Multiple Sclerosis News Today

    stay in a relapsing stage or use disease-modifying therapies (DMTs) for longer periods are less likely to transition to secondary progressive multiple sclerosis (SPMS) than others, according to a study based on the Italian MS registry. But patients...

    https://mschristian.org/index.php/blog/ectrims2019-longer-dmt-use-and-female-sex-seen-to-protect-against-spms-conversion-multiple-sclerosis-news-today
  • Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

    to reduce the annualized relapse rate over Aubagio®* (teriflunomide) in patients with relapsing forms of MS (RMS)[1] Key secondary endpoints of delaying time to confirmed disability progression were also met[1]; additional secondary endpoints will be...

    https://mschristian.org/index.php/articles/2-uncategorised/8790-novartis-ofatumumab-demonstrates-superiority-versus-aubagio-in-two-head-to-head-phase-iii-multiple-sclerosis-studies-1
  • MS Risk Nearly Doubles 15 Years Following Teen Concussion - Medscape

    "We also found a significantly increased risk among males and not females" starting at about 8 years post-concussion in a secondary analysis, lead study author Christopher Povolo, BSc, of the Department of Clinical Neurological Sciences, Schulich School...

    https://mschristian.org/index.php/articles/2-uncategorised/8693-ms-risk-nearly-doubles-15-years-following-teen-concussion-medscape

Results 1 - 20 of 70